ICICI Direct is bullish on Divi's Laboratories has recommended buy rating on the stock with a target price of Rs 3260 in its research report dated August 09, 2020.
ICICI Direct's research report on Divi's Laboratories
Mahindra & Mahindra (M&M) reported a relatively healthy operational performance in Q1FY21. Standalone net sales fell 56.6% YoY. Automotive ASPs surprised positively, coming in at Rs 6.9 lakh/unit while ASP for farm equipment segment (FES) i.e. tractor was at Rs 5.1 lakh/unit. Standalone EBITDA in Q1FY21 was at Rs 549 crore with corresponding EBITDA margins at 9.8% (down 261 bps QoQ), primarily tracking a rise in staff costs (percentage of sales basis). Automotive segment posted EBIT loss of Rs 576 crore while EBIT margins in FES expanded strongly by 280 bps QoQ to 20.4%. Consequent standalone PAT for the quarter came in at Rs 112 crore, crimped by lower other income and higher interest costs.
We expect sales, EBITDA to grow at 5%, 11.6% CAGR, respectively, in FY20-22E. We continue to like M&M for its strong rural presence and sharpened capital allocation focus, although pace of recovery on automotive side remains a monitorable. We maintain BUY rating on M&M, valuing it at Rs 700/share on SOTP basis (7.5x FY22E EV/EBITDA for base business; 30% holdco discount to its investments).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.